Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ultra‐radical (extensive) surgery vs standard surgery Progression‐free survival · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | HR 0.62 [0.42, 0.92] | 1 study · 203 participants | Very low |
Ultra‐radical (extensive) surgery vs standard surgery Disease‐free survival · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | HR 1.6 [1.11, 2.31] | 1 study · 527 participants | Very low |
Ultra‐radical (extensive) surgery vs standard surgery Rate of optimal cytoreduction · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | no estimate extracted | NR | High |
Ultra‐radical (extensive) surgery vs standard surgery Recurrence rate · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultra‐radical (extensive) surgery vs standard surgery (Loco)regional control · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | no estimate extracted | NR | No studies |
Ultra‐radical (extensive) surgery vs standard surgery Adverse event: perioperative mortality · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | no estimate extracted | 2 studies · 397 participants | Very low |
Ultra‐radical (extensive) surgery vs standard surgery Adverse event: serious postoperative morbidity · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | RR 3.24 [1.84, 5.68] | 1 study · 203 participants | Very low |
Ultra‐radical (extensive) surgery vs standard surgery Quality of Life · women with stage IIIc or IV ovarian cancer Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone Outcomes · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy) Any severe adverse event (grade 3 or higher) (G3+ SevAE ) · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | RR 2.87 [1.65, 4.99] | 2 studies · 1118 participants | Very low |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy Outcomes · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy Overall survival (OS) · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | HR 0.95 [0.62, 1.47] | 2 studies · 331 participants | Low |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy Progression‐free survival (PFS) · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | HR 0.88 [0.56, 1.38] | 3 studies · 739 participants | Very low |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy Quality of Life (QoL) · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | 1 study · 229 participants | Low |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy Any severe adverse event (grade 3 or higher) (G3+ SevAE) · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | RR 1.06 [0.8, 1.39] | 1 study · 254 participants | Low |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo after chemotherapy (maintenance therapy) Outcomes · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo after chemotherapy (maintenance therapy) Overall survival (OS) · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | HR 0.88 [0.65, 1.2] | 2 studies · 560 participants | Moderate |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo after chemotherapy (maintenance therapy) Progression‐free survival (PFS) · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | HR 0.34 [0.28, 0.42] | 4 studies · 1677 participants | High |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo after chemotherapy (maintenance therapy) Quality of Life ‐ European Quality of Life 5‐dimensionsquestionnaire ‐ Participants with BRCA mutation (QoL) · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | 1 study · 339 participants | Moderate |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone Overall survival ‐ not reported · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo after chemotherapy (maintenance therapy) Any severe adverse event (grade 3 or higher) (G3+ SevAE) · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | RR 2.62 [1.85, 3.72] | 4 studies · 1665 participants | Low |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone Outcomes · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone Overall survival (OS) · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | 1 study · 1 participants | Ungraded |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone Progression‐free survival (PFS) · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | HR 1.02 [0.69, 1.51] | 1 study · 75 participants | Very low |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone Quality of Life ‐ not reported · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone Any severe adverse event (grade 3 or higher) (G3+ SevAE) · platinum‐sensitive recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | RR 1.14 [0.89, 1.47] | 1 study · 156 participants | Low |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy Outcomes · platinum‐resistant recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy Overall survival ‐ not reported · platinum‐resistant recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy Progression‐free survival ‐ not reported · platinum‐resistant recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy Any severe adverse events (grade 3 or higher) (G3+ SevAE) · platinum‐resistant recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | RR 1.16 [0.79, 1.7] | 1 study · 100 participants | Very low |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone Progression‐free survival (PFS) · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | HR 0.82 [0.49, 1.38] | 2 studies · 1564 participants | Very low |
Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy Quality of Life ‐ not reported · platinum‐resistant recurrent EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone Quality of life (QoL) · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | 1 study · 744 participants | Moderate |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone Any severe adverse event (grade 3 or higher) (G3+ SevAE) · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | RR 1.13 [1.07, 1.2] | 2 studies · 1549 participants | High |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy) Outcomes · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy) Overall survival (OS) · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | HR 0.81 [0.59, 1.13] | 2 studies · 1124 participants | Moderate |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy) Progression‐free survival (PFS) · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | HR 0.42 [0.19, 0.92] | 2 studies · 1124 participants | Low |
Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy) Quality of Life (QoL) · newly‐diagnosed EOC Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer (2022) · Cochrane | no estimate extracted | 1 study · 362 participants | Moderate |
Enhanced recovery after surgery programme vs traditional care Length of postoperative hospital stay · women with gynaecological cancers Perioperative enhanced recovery programmes for women with gynaecological cancers (2022) · Cochrane | no estimate extracted | 6 studies · 638 participants | Low |
Enhanced recovery after surgery programme vs traditional care Overall postoperative complications (within 30 days of operation) · women with gynaecological cancers Perioperative enhanced recovery programmes for women with gynaecological cancers (2022) · Cochrane | RR 0.71 [0.48, 1.05] | 5 studies · 537 participants | Low |
Enhanced recovery after surgery programme vs traditional care Mortality (within 30 days of discharge) · women with gynaecological cancers Perioperative enhanced recovery programmes for women with gynaecological cancers (2022) · Cochrane | RR 0.98 [0.14, 6.68] | 1 study · 99 participants | Very low |
Enhanced recovery after surgery programme vs traditional care Readmission (within 30 days of operation) · women with gynaecological cancers Perioperative enhanced recovery programmes for women with gynaecological cancers (2022) · Cochrane | RR 0.45 [0.22, 0.9] | 3 studies · 385 participants | Low |
Enhanced recovery after surgery programme vs traditional care Time to first flatus (bowel function) · women with gynaecological cancers Perioperative enhanced recovery programmes for women with gynaecological cancers (2022) · Cochrane | no estimate extracted | 4 studies · 432 participants | Low |
Enhanced recovery after surgery programme vs traditional care Time to first defaecation (bowel function) · women with gynaecological cancers Perioperative enhanced recovery programmes for women with gynaecological cancers (2022) · Cochrane | no estimate extracted | 2 studies · 228 participants | Low |
Enhanced recovery after surgery programme vs traditional care Participant satisfaction · women with gynaecological cancers Perioperative enhanced recovery programmes for women with gynaecological cancers (2022) · Cochrane | no estimate extracted | 2 studies · 228 participants | Very low |
Enhanced recovery after surgery programme vs traditional care Economic outcomes · women with gynaecological cancers Perioperative enhanced recovery programmes for women with gynaecological cancers (2022) · Cochrane | no estimate extracted | 2 studies · 167 participants | Very low |
Weekly paclitaxel vs three‐weekly paclitaxel Overall survival · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | HR 0.94 [0.66, 1.33] | 2 studies · 263 participants | Very low |
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Overall survival · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | HR 0.97 [0.77, 1.23] | 1 study · 330 participants | Low |
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Response rate · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | RR 0.86 [0.4, 1.89] | 1 study · 265 participants | Very low |
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Response rate ‐ platinum‐sensitive · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | RR 0.6 [0.39, 0.93] | 1 study · 213 participants | Low |